ArriVent BioPharma Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Bing Yao
Chief executive officer
US$1.2m
Total compensation
| CEO salary percentage | 45.2% |
| CEO tenure | 3.6yrs |
| CEO ownership | 0.6% |
| Management average tenure | 1.3yrs |
| Board average tenure | 1.8yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$81m |
| Jun 30 2024 | n/a | n/a | -US$75m |
| Mar 31 2024 | n/a | n/a | -US$75m |
| Dec 31 2023 | US$1m | US$536k | -US$69m |
| Sep 30 2023 | n/a | n/a | -US$59m |
| Jun 30 2023 | n/a | n/a | -US$56m |
| Mar 31 2023 | n/a | n/a | -US$42m |
| Dec 31 2022 | US$1m | US$516k | -US$37m |
Compensation vs Market: Bing's total compensation ($USD1.19M) is below average for companies of similar size in the US market ($USD3.21M).
Compensation vs Earnings: Bing's compensation has been consistent with company performance over the past year.
CEO
Bing Yao (58 yo)
3.6yrs
Tenure
US$1,185,782
Compensation
Dr. Zhengbin Yao, also known as Bing, Ph D., is the Co-Founder, Chairman, President and Chief Executive Officer of ArriVent Biopharma, Inc. and also serves as a Director since June 2021. Dr. Yao serves as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | no data | US$1.19m | 0.65% $ 5.7m | |
| Co-Founder | no data | US$828.75k | 0.44% $ 3.9m | |
| Co-Founder & COO | 1.4yrs | US$960.99k | 1.54% $ 13.6m | |
| CFO & Treasurer | less than a year | no data | no data | |
| Chief Technology Officer | no data | no data | no data | |
| General Counsel & Secretary | 1.3yrs | no data | 0.022% $ 193.2k | |
| Senior Vice President of Commercial Strategy | no data | no data | no data |
1.3yrs
Average Tenure
52yo
Average Age
Experienced Management: AVBP's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 3.6yrs | US$1.19m | 0.65% $ 5.7m | |
| Co-Founder | 3.6yrs | US$828.75k | 0.44% $ 3.9m | |
| Director | 2.1yrs | no data | no data | |
| Independent Director | 1.8yrs | no data | no data | |
| Director | less than a year | no data | no data | |
| Director | less than a year | no data | no data | |
| Independent Director | 1.3yrs | US$79.28k | no data |
1.8yrs
Average Tenure
64yo
Average Age
Experienced Board: AVBP's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 00:30 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ArriVent BioPharma, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yigal Nochomovitz | Citigroup Inc |
| Corinne Johnson | Goldman Sachs |
| Robert Burns | H.C. Wainwright & Co. |